Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections

Minah Park; Kelvin Bryan Tan; Shawn Vasoo; Borame L Dickens; David Lye; Alex R Cook

doi:10.1001/jamanetworkopen.2022.5750

Estimated Health Outcomes and Costs Associated With Use of Monoclonal Antibodies for Prevention or Mitigation of SARS-CoV-2 Infections

JAMA Netw Open. 2022 Apr 1;5(4):e225750. doi: 10.1001/jamanetworkopen.2022.5750.

Authors

Minah Park¹, Kelvin Bryan Tan², Shawn Vasoo³, Borame L Dickens¹, David Lye³, Alex R Cook¹

Affiliations

¹ Saw Swee Hock School of Public Health, National University of Singapore, Singapore.
² Ministry of Health, Singapore.
³ National Centre for Infectious Diseases, Singapore.

Abstract

This economic evaluation investigates the health outcomes and costs associated with use of monoclonal antibodies for treatment of SARS-CoV-2 in 14 scenarios stratified by age, vaccination status, and source of infection.

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Viral
COVID-19*
Humans
Outcome Assessment, Health Care
SARS-CoV-2

Substances

Antibodies, Monoclonal
Antibodies, Viral